1
|
Porter T, Kucheryavykh L. F10 Gene Expression and Ethnic Disparities Present in Papillary Thyroid Carcinoma. J Pers Med 2024; 14:524. [PMID: 38793106 PMCID: PMC11122589 DOI: 10.3390/jpm14050524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2024] [Revised: 05/02/2024] [Accepted: 05/10/2024] [Indexed: 05/26/2024] Open
Abstract
Papillary thyroid carcinoma (PTC) presents a significant health concern, particularly among Hispanic women in the United States, who exhibit a disproportionately higher chance of developing an advanced disease when compared to the non-Hispanic population. Emerging evidence suggests coagulation factor X, encoded by the F10 gene, has a potential role in inhibiting cancer cell migration. However, comprehensive investigations into the differential expression patterns of F10 in Hispanic versus non-Hispanic females remain limited. RNA-sequencing data were acquired from the TCGA database for white female patients, 166 non-Hispanic and 25 Hispanic. A statistically significant (p < 0.05) 2.06-fold increase in F10 expression levels was detected in disease-free tumors compared to recurrent PTC tumors. Furthermore, an increase in F10 gene expression levels was also observed, corresponding to approximately a 1.74-fold increase in non-Hispanic patients compared to Hispanic patients. The probability of tumor recurrence was 1.82 times higher in the cohort with low expression of F10 compared to the high-expression cohort, correlating with the lower disease-free rates observed in the Hispanic patient cohort when compared to non-Hispanics. This finding underscores the relevance of ethnic disparities in molecular profiles for understanding cancer susceptibility. Identifying F10 as a potential prognostic biomarker highlights avenues for targeted interventions and contributes to improving diagnostic and treatment strategies for diverse patient populations.
Collapse
Affiliation(s)
- Tyrel Porter
- Department of Biochemistry, Universidad Central del Caribe, Bayamón, PR 00956, USA;
| | | |
Collapse
|
2
|
Li X, Ding Z, Tong Y. Identification of SUMOylation-related biomarkers in papillary thyroid carcinoma. Cancer Cell Int 2024; 24:149. [PMID: 38671425 PMCID: PMC11055338 DOI: 10.1186/s12935-024-03323-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2024] [Accepted: 04/06/2024] [Indexed: 04/28/2024] Open
Abstract
BACKGROUND Small ubiquitin-like modifier (SUMO) modification is increasingly recognized as critical in tumorigenesis and progression. This study identifies biomarkers linked to SUMOylation in papillary thyroid carcinoma (PTC), aiming to advance therapeutic and prognostic strategies. METHODS Employing PTC datasets and SUMO related genes (SRGs), we utilized univariate Cox regression for prognosis-related SRGs, conducted differential expression analyses, and integrated findings to pinpoint candidate genes. These genes underwent further validation through survival, gene set enrichment, immune infiltration, and drug sensitivity analyses, including external validation via quantitative RT-qPCR. In our final step, we conducted immunohistochemical staining on tumor samples from PTC patients at our center and integrated this with their clinical data to validate BMP8A's effectiveness in predicting recurrence in PTC. RESULTS Three biomarkers-BMP8A, RGS8, and SERPIND1-emerged as significant. Gene Set Enrichment Analysis (GSEA) showed their involvement in immune-related pathways, with differential immune infiltration patterns and drug response correlations observed, underscoring their potential for targeted therapy. Lastly, we validated the efficacy of BMP8A in predicting the recurrence of PTC in patients using clinical and pathological data from our center. CONCLUSION The study identifies BMP8A, RGS8, and SERPIND1 as key biomarkers associated with SUMOylation in PTC. Their linkage to immune response and drug sensitivity highlights their importance as targets for therapeutic intervention and prognosis in PTC research.
Collapse
Affiliation(s)
- Xiang Li
- Department of General Surgery, The Affiliated Hospital of Jiujiang University, Jiujiang, China
| | - Zigang Ding
- Department of General Surgery, The Affiliated Hospital of Jiujiang University, Jiujiang, China
| | - Yun Tong
- Department of Pain, The Affiliated Hospital of Jiujiang University, No. 57 East Xunyang Road, Jiujiang, 332000, Jiangxi, China.
| |
Collapse
|
3
|
Ywata de Carvalho A, Kohler HF, Ywata de Carvalho CCG, Vartanian JG, Kowalski LP. Predictors of recurrence after total thyroidectomy in 1,611 patients with papillary thyroid carcinoma: postoperative stimulated serum thyroglobulin and ATA initial and dynamic risk assessment. ARCHIVES OF ENDOCRINOLOGY AND METABOLISM 2024; 68:e220506. [PMID: 38578436 PMCID: PMC11081051 DOI: 10.20945/2359-4292-2022-0506] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/21/2023] [Accepted: 10/02/2023] [Indexed: 04/06/2024]
Abstract
Objective Despite a favorable prognosis, some patients with papillary thyroid carcinoma (PTC) develop recurrence. The objective of this study was to examine the impact of the combination of initial American Thyroid Association (ATA) risk stratification with serum level of postoperative stimulated thyroglobulin (s-Tg) in predicting recurrence in patients with PTC and compare the results with an assessment of response to initial therapy (dynamic risk stratification). Subjects and methods We retrospectively analyzed 1,611 patients who had undergone total thyroidectomy for PTC, followed in most cases (87.3%) by radioactive iodine (RAI) administration. Clinicopathological features and s-Tg levels obtained 3 months postoperatively were evaluated. The patients were stratified according to ATA risk categories. Nonstimulated thyroglobulin levels and imaging studies obtained during the first year of follow-up were used to restage the patients based on response to initial therapy. Results After a mean follow-up of 61.5 months (range 12-246 months), tumor recurrence was diagnosed in 99 (6.1%) patients. According to ATA risk, recurrence was identified in 2.3% of the low-risk, 9% of the intermediate-risk, and 25% of the high-risk patients (p < 0.001). Using a receiver operating characteristic curve approach, a postoperative s-Tg level of 10 ng/mL emerged as the ideal cutoff value, with positive and negative predictive values of 24% and 97.8%, respectively (p < 0.001). Patients with low to intermediate ATA risk with postoperative s-Tg levels < 10 ng/mL and excellent response to treatment had a very low recurrence rate (<0.8%). In contrast, higher recurrence rates were observed in intermediate-riskto high-risk patients with postoperative s-Tg > 10 ng/mL and indeterminate response (25%) and in those with incomplete response regardless of ATA category or postoperative s-Tg value (38.5-87.5%). Using proportion of variance explained (PVE), the predicted recurrence using the ATA initial risk assessment alone was 12.7% and increased to 29.9% when postoperative s-Tg was added to the logistic regression model and 49.1% with dynamic risk stratification. Conclusion The combination of ATA staging system and postoperative s-Tg can better predict the risk of PTC recurrence. Initial risk estimates can be refined based ondynamic risk assessment following response to therapy, thus providing a useful guide for follow-up recommendations.
Collapse
Affiliation(s)
- Andre Ywata de Carvalho
- A.C. Camargo Cancer Center, Departamento de Cirurgia de Cabeça e Pescoço e Otorrinolaringologia, São Paulo, SP, Brasil,
| | - Hugo Fontan Kohler
- A.C. Camargo Cancer Center, Departamento de Cirurgia de Cabeça e Pescoço e Otorrinolaringologia, São Paulo, SP, Brasil
| | | | - Jose Guilherme Vartanian
- A.C. Camargo Cancer Center, Departamento de Cirurgia de Cabeça e Pescoço e Otorrinolaringologia, São Paulo, SP, Brasil
| | - Luiz Paulo Kowalski
- A.C. Camargo Cancer Center, Departamento de Cirurgia de Cabeça e Pescoço e Otorrinolaringologia, São Paulo, SP, Brasil
- Faculdade de Medicina, Departamento de Cirurgia de Cabeça e Pescoço, Universidade de São Paulo, São Paulo, SP, Brasil
| |
Collapse
|
4
|
Ju SH, Ji YB, Song M, Lim JY, Heo DB, Kim MG, Chang JW, Won HR, Kang YE, Ku EJ, Kim M, Lee EK, Choi JY, Yu HW, Park YJ, Choe JH, Koo BS. Feasibility of active surveillance in patients with clinically T1b papillary thyroid carcinoma ≤1.5 cm in preoperative ultrasonography: MASTER study. Eur Thyroid J 2024; 13:e230258. [PMID: 38484463 PMCID: PMC11046321 DOI: 10.1530/etj-23-0258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/07/2023] [Accepted: 03/13/2024] [Indexed: 04/21/2024] Open
Abstract
Objective Active surveillance (AS) is generally accepted as an alternative to immediate surgery for papillary thyroid carcinoma (PTC) measuring ≤1.0 cm (cT1a) without risk factors. This study investigated the clinicopathologic characteristics of PTCs measuring ≤2.0 cm without cervical lymph node metastasis (cT1N0) by tumor size group to assess the feasibility of AS for PTCs between 1.0 cm and 1.5 cm (cT1b≤1.5). Design This study enrolled clinically T1N0 patients with preoperative ultrasonography information (n= 935) from a cohort of 1259 patients who underwent lobectomy and were finally diagnosed with PTC from June 2020 to March 2022. Results The cT1b≤1.5 group (n = 171; 18.3 %) exhibited more lymphatic invasion and occult central lymph node (LN) metastasis with a higher metastatic LN ratio than the cT1a group (n = 719; 76.9 %). However, among patients aged 55 years or older, there were no significant differences in occult central LN metastasis and metastatic LN ratio between the cT1a, cT1b≤1.5, and cT1b>1.5 groups. Multivariate regression analyses revealed that occult central LN metastasis was associated with age, sex, tumor size, extrathyroidal extension, and lymphatic invasion in patients under 55, while in those aged 55 or older, it was associated only with age and lymphatic invasion. Conclusion For PTC patients aged 55 years or older with cT1b≤1.5, AS could be a viable option due to the absence of a significant relationship between tumor size and occult central LN.
Collapse
Affiliation(s)
- Sang-Hyeon Ju
- Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea
| | - Yong Bae Ji
- Department of Otolaryngology–Head and Neck Surgery, Hanyang University College of Medicine, Seoul, Republic of Korea
| | - Minchul Song
- Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea
| | - Joung Youl Lim
- Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea
| | - Da Beom Heo
- Department of Otorhinolaryngology–Head and Neck Surgery, Chungnam National University Hospital, Daejeon, Republic of Korea
| | - Min-Gyu Kim
- Department of Otorhinolaryngology–Head and Neck Surgery, Chungnam National University Hospital, Daejeon, Republic of Korea
| | - Jae Won Chang
- Department of Otorhinolaryngology–Head and Neck Surgery, Chungnam National University Hospital, Daejeon, Republic of Korea
- Department of Otorhinolaryngology–Head and Neck Surgery, Chungnam National University College of Medicine, Daejeon, Republic of Korea
| | - Ho-Ryun Won
- Department of Otorhinolaryngology–Head and Neck Surgery, Chungnam National University College of Medicine, Daejeon, Republic of Korea
- Department of Otorhinolaryngology–Head and Neck Surgery, Chungnam National University Sejong Hospital, Sejong, Republic of Korea
| | - Yea Eun Kang
- Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Republic of Korea
| | - Eu Jeong Ku
- Department of Internal Medicine, Seoul National University Hospital Healthcare System Gangnam Center, Seoul, Republic of Korea
| | - Mijin Kim
- Department of Internal Medicine, Pusan National University Hospital, Busan, Republic of Korea
| | - Eun Kyung Lee
- Department of Internal Medicine, Center for Thyroid Cancer, National Cancer Center, Goyang-si, Republic of Korea
| | - June Young Choi
- Department of Surgery, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea
| | - Hyeong Won Yu
- Department of Surgery, Seoul National University Bundang Hospital, Seongnam-si, Republic of Korea
| | - Young Joo Park
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Jun-Ho Choe
- Division of Endocrine Surgery, Department of Surgery, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea
| | - Bon Seok Koo
- Department of Otorhinolaryngology–Head and Neck Surgery, Chungnam National University Hospital, Daejeon, Republic of Korea
- Department of Otorhinolaryngology–Head and Neck Surgery, Chungnam National University College of Medicine, Daejeon, Republic of Korea
| | | |
Collapse
|
5
|
Chidambaranathan N, Thiagarajan S, Gurukeerthi B, Sathe P, Samel P, Ramalingam N, Chaukar D. The significance of the presence of extranodal extension in the metastatic node of differentiated thyroid cancer: a proposal for modification in the American Thyroid Association (ATA) risk stratification. Eur Arch Otorhinolaryngol 2024; 281:1923-1931. [PMID: 38189969 DOI: 10.1007/s00405-023-08438-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2023] [Accepted: 12/23/2023] [Indexed: 01/09/2024]
Abstract
BACKGROUND Multiple factors contribute to recurrences in differentiated thyroid cancers (DTC). Though the nodal size and number of positive nodes along with the presence of extranodal extension (ENE) have been mentioned in the present ATA risk stratification, the weightage given for ENE seems inadequate compared to the former two. METHODOLOGY Factors predicting recurrences were analysed in this retrospective study of patients with DTC operated in a tertiary care centre. Based on our findings, we propose a modification in the present risk stratification. We have done so by comparing with existing risk stratification for fit and discrimination of this system. RESULTS Out of 1428 patients, 859 (60.2%) patients had pathological nodal metastases (pN +) with ENE being present in 26.8% of these. The recurrence rate was 6.4% (92 patients). Recurrence rates in patients with ≤ 5 nodes without ENE, > 5 nodes without ENE, ≤ 5 nodes with ENE and > 5 nodes with ENE were 2.7%, 1.3%, 8.3% and 10.3%, respectively. Recurrence rates in patients with 0.2-3 cm without ENE, 0.2-3 cm with ENE and > 3 cm with/without ENE were 1.8%, 8.5% and 13.4%, respectively. A modified risk stratification incorporating ENE and excluding the number of metastatic nodes was proposed. The modified risk stratification had a better fit than the present system in terms of higher C index and lower AIC. CONCLUSIONS Extranodal extension in differentiated thyroid cancer had the maximum influence on recurrence risk (recurrence-free survival) in our cohort. The prognostic impact of ENE supersedes the number of positive nodes in the risk of recurrence.
Collapse
Affiliation(s)
| | - Shivakumar Thiagarajan
- Department of Head and Neck Oncology, Tata Memorial Centre and Homi Bhabha National Institute (HBNI), Mumbai, India.
| | - B Gurukeerthi
- Department of Head and Neck Oncology, Tata Memorial Centre and Homi Bhabha National Institute (HBNI), Mumbai, India
| | - Pranav Sathe
- Department of Head and Neck Oncology, Tata Memorial Centre and Homi Bhabha National Institute (HBNI), Mumbai, India
| | - Priyanka Samel
- Department of Head and Neck Oncology, Tata Memorial Centre and Homi Bhabha National Institute (HBNI), Mumbai, India
| | | | - Devendra Chaukar
- Department of Head and Neck Oncology, Max Nanavati Hospital, Mumbai, India
| |
Collapse
|
6
|
Regmi S, Farazi PA, Lyden E, Kotwal A, Ganti AK, Goldner W. Disparities in Thyroid Cancer Diagnosis Based on Residence and Distance From Medical Facility. J Endocr Soc 2024; 8:bvae033. [PMID: 38481601 PMCID: PMC10928505 DOI: 10.1210/jendso/bvae033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/02/2024] [Indexed: 04/07/2024] Open
Abstract
Context Rural-urban disparities have been reported in cancer care, but data are sparse on the effect of geography and location of residence on access to care in thyroid cancer. Objective To identify impact of rural or urban residence and distance from treatment center on thyroid cancer stage at diagnosis. Methods We evaluated 800 adults with differentiated thyroid cancer in the iCaRe2 bioinformatics/biospecimen registry at the Fred and Pamela Buffett Cancer Center. Participants were categorized into early and late stage using AJCC staging, and residence/distance from treating facility was categorized as short (≤ 12.5 miles), intermediate (> 12.5 to < 50 miles) or long (≥ 50 miles). Multivariable logistic regression was used to identify factors associated with late-stage diagnosis. Results Overall, 71% lived in an urban area and 29% lived in a rural area. Distance from home to the treating facility was short for 224 (28%), intermediate for 231 (28.8%), and long for 345 (43.1%). All 224 (100%) short, 226 (97.8%) intermediate, and 120 (34.7%) long distances were for urban patients; in contrast, among rural patients, 5 (2.16%) lived intermediate and 225 (65.2%) lived long distances from treatment (P < .0001). Using eighth edition AJCC staging, the odds ratio of late stage at diagnosis for rural participants ≥ 55 years was 2.56 (95% CI, 1.08-6.14) (P = .03), and for those living ≥ 50 miles was 4.65 (95% CI, 1.28-16.93) (P = .0075). Results were similar using seventh edition AJCC staging. Conclusion Older age at diagnosis, living in rural areas, and residing farther from the treatment center are all independently associated with late stage at diagnosis of thyroid cancer.
Collapse
Affiliation(s)
- Sunita Regmi
- Kansas Department of Health and Environment, Bureau of Epidemiology and Public Health Informatics, Curtis State Office Building, 1000 SW Jackson ST., Suite 130, Topeka, KS 66612-1365, USA
- Department of Epidemiology, University of Nebraska Medical Center, College of Public Health, Omaha, NE 68198, USA
| | - Paraskevi A Farazi
- Department of Epidemiology, University of Nebraska Medical Center, College of Public Health, Omaha, NE 68198, USA
- School of Medicine, European University Cyprus, 6 Diogenous Street, 2404 Engomi, Nicosia, Cyprus
| | - Elizabeth Lyden
- Department of Biostatistics, University of Nebraska Medical Center, College of Public Health, Omaha, NE 68198, USA
| | - Anupam Kotwal
- Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, University of Nebraska Medical Center, Omaha, NE 68198, USA
| | - Apar Kishor Ganti
- Department of Medicine, Division of Hematology and Oncology, University of Nebraska Medical Center, Omaha, NE 68198, USA
- VA Nebraska Western Iowa Health Care System, 4101 Woolworth Avenue, Omaha, NE 68105-1850, USA
| | - Whitney Goldner
- Department of Medicine, Division of Diabetes, Endocrinology and Metabolism, University of Nebraska Medical Center, Omaha, NE 68198, USA
| |
Collapse
|
7
|
Poyil PK, Siraj AK, Padmaja D, Parvathareddy SK, Thangavel S, Alobaisi K, Diaz R, Begum R, Haqawi W, Al‐Sobhi SS, Al‐Dayel F, Al‐Kuraya KS. PLK1 and FoxM1 expressions positively correlate in papillary thyroid carcinoma and their combined inhibition results in synergistic anti-tumor effects. Mol Oncol 2024; 18:691-706. [PMID: 38361222 PMCID: PMC10920088 DOI: 10.1002/1878-0261.13610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2023] [Revised: 11/14/2023] [Accepted: 02/06/2024] [Indexed: 02/17/2024] Open
Abstract
Polo-like kinase 1 (PLK1; also known as serine/threonine-protein kinase PLK1) serves as a central player in cell proliferation, exerting critical regulatory roles in mitotic processes and cell survival. We conducted an analysis of PLK1 protein expression in a large cohort of samples from papillary thyroid carcinoma (PTC) patients and examined its functional significance in PTC cell lines, both in vitro and in vivo. PLK1 overexpression was noted in 54.2% of all PTC and was significantly associated with aggressive clinicopathological parameters; it was also found to be an independent prognostic marker for shorter recurrence-free survival. Given the significant association between PLK1 and forkhead box protein M1 (FoxM1), and their concomitant overexpression in a large proportion of PTC samples, we explored their correlation and their combined inhibitions in PTC in vitro and in vivo. Inhibition of PLK1 expression indeed suppressed cell proliferation, leading to cell cycle arrest and apoptosis in PTC cell lines. Significantly, the downregulation of PLK1 reduced the self-renewal capability of spheroids formed from PTC cells. Immunoprecipitation analysis shows that PLK1 binds to FoxM1 and vice versa in vitro. Mechanistically, PLK1 knockdown suppresses FoxM1 expression, whereas inhibition of FoxM1 does not affect PLK1 expression, which suggests that PLK1 acts through the FoxM1 pathway. The combined treatment of a PLK1 inhibitor (volasertib) and a FoxM1 inhibitor (thiostrepton) demonstrated a synergistic effect in reducing PTC cell growth in vitro and delaying tumor growth in vivo. This study highlights the important role of PLK1 in PTC tumorigenesis and prognosis. It also highlights the synergistic therapeutic potential of dual-targeting PLK1 and FoxM1 in PTC, unveiling a potential innovative therapeutic strategy for managing aggressive forms of PTC.
Collapse
Affiliation(s)
- Pratheesh Kumar Poyil
- Human Cancer Genomic ResearchKing Faisal Specialist Hospital and Research CenterRiyadhSaudi Arabia
| | - Abdul K. Siraj
- Human Cancer Genomic ResearchKing Faisal Specialist Hospital and Research CenterRiyadhSaudi Arabia
| | - Divya Padmaja
- Human Cancer Genomic ResearchKing Faisal Specialist Hospital and Research CenterRiyadhSaudi Arabia
| | | | - Saravanan Thangavel
- Human Cancer Genomic ResearchKing Faisal Specialist Hospital and Research CenterRiyadhSaudi Arabia
| | - Khadija Alobaisi
- Human Cancer Genomic ResearchKing Faisal Specialist Hospital and Research CenterRiyadhSaudi Arabia
| | - Roxanne Diaz
- Human Cancer Genomic ResearchKing Faisal Specialist Hospital and Research CenterRiyadhSaudi Arabia
| | - Rafia Begum
- Human Cancer Genomic ResearchKing Faisal Specialist Hospital and Research CenterRiyadhSaudi Arabia
| | - Wael Haqawi
- Human Cancer Genomic ResearchKing Faisal Specialist Hospital and Research CenterRiyadhSaudi Arabia
| | - Saif S. Al‐Sobhi
- Department of SurgeryKing Faisal Specialist Hospital and Research CentreRiyadhSaudi Arabia
| | - Fouad Al‐Dayel
- Department of PathologyKing Faisal Specialist Hospital and Research CentreRiyadhSaudi Arabia
| | - Khawla S. Al‐Kuraya
- Human Cancer Genomic ResearchKing Faisal Specialist Hospital and Research CenterRiyadhSaudi Arabia
| |
Collapse
|
8
|
Pałyga I, Rumian M, Kosel A, Albrzykowski M, Krawczyk P, Kalwat A, Gąsior-Perczak D, Walczyk A, Kuchareczko A, Kopczyński J, Chrapek M, Góźdź S, Kowalska A. The Frequency of Differentiated Thyroid Cancer Recurrence in 2302 Patients With Excellent Response to Primary Therapy. J Clin Endocrinol Metab 2024; 109:e569-e578. [PMID: 37768152 DOI: 10.1210/clinem/dgad571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/01/2023] [Revised: 08/18/2023] [Accepted: 09/27/2023] [Indexed: 09/29/2023]
Abstract
CONTEXT Discrepant data on the recurrence rate of differentiated thyroid cancer (DTC) are reported. OBJECTIVE To evaluate the frequency and risk factors of true recurrence in DTC patients with excellent responses (ExR) to initial therapy. METHODS A retrospective analysis of the 2302 consecutive DTC patients with ExR to primary therapy, treated during 24 years at single center. The percentage of recurrence and cumulative recurrence rate (CRR) were analyzed. Risk factors for recurrence for patients with papillary thyroid cancer (PTC) were investigated and methods for establishing a diagnosis of recurrence were evaluated. RESULTS Of DTC patients, 32 (1.4%) experienced recurrence. PTC patients with recurrence were more likely to have younger age (P = .0182), larger tumor size (P = .0013), lymph node metastases (P = .0013), incomplete resection (P = .0446), higher ATA risk (P = .0002), and had more frequently been treated with 131I (P = .0203). CRRs at 5, 10, 15, 20, and 24 years after surgery were 1.2%, 1.9%, 2.5%, 2.9%, and 2.9%, respectively. The CRRs according to histological type were highest for poorly differentiated thyroid cancer (PDTC), lower for oncocytic (OTC) and follicular thyroid cancer (FTC), and lowest for PTC. Most recurrences occurred within the first 5 years of observation. The most effective method for detecting local recurrence was ultrasonography with fine needle aspiration cytology, and for distant metastases, 18F-FDG PET. CONCLUSION True recurrence is rare in DTC patients. PTC patients with ExR to primary therapy and N0/Nx can be dismissed from oncological follow-up. Despite ExR to primary therapy, DTC patients with N1, and PDTC, OTC, FTC should remain under oncological follow-up.
Collapse
Affiliation(s)
- Iwona Pałyga
- Collegium Medicum, Jan Kochanowski University, Kielce 25-317, Poland
- Endocrinology Clinic, Holycross Cancer Centre, Kielce 25-734, Poland
| | - Maciej Rumian
- Collegium Medicum, Jan Kochanowski University, Kielce 25-317, Poland
| | - Alicja Kosel
- Collegium Medicum, Jan Kochanowski University, Kielce 25-317, Poland
| | | | - Paulina Krawczyk
- Collegium Medicum, Jan Kochanowski University, Kielce 25-317, Poland
| | - Agata Kalwat
- Collegium Medicum, Jan Kochanowski University, Kielce 25-317, Poland
| | - Danuta Gąsior-Perczak
- Collegium Medicum, Jan Kochanowski University, Kielce 25-317, Poland
- Endocrinology Clinic, Holycross Cancer Centre, Kielce 25-734, Poland
| | - Agnieszka Walczyk
- Collegium Medicum, Jan Kochanowski University, Kielce 25-317, Poland
- Endocrinology Clinic, Holycross Cancer Centre, Kielce 25-734, Poland
| | - Artur Kuchareczko
- Collegium Medicum, Jan Kochanowski University, Kielce 25-317, Poland
- Endocrinology Clinic, Holycross Cancer Centre, Kielce 25-734, Poland
| | - Janusz Kopczyński
- Department of Pathology, Holycross Cancer Centre, Kielce 25-734, Poland
| | - Magdalena Chrapek
- Department of Mathematics, Faculty of Natural Sciences, Jan Kochanowski University, Kielce 25-406, Poland
| | - Stanisław Góźdź
- Collegium Medicum, Jan Kochanowski University, Kielce 25-317, Poland
- Department of Clinical Oncology, Holycross Cancer Centre, Kielce 25-734, Poland
| | - Aldona Kowalska
- Collegium Medicum, Jan Kochanowski University, Kielce 25-317, Poland
- Endocrinology Clinic, Holycross Cancer Centre, Kielce 25-734, Poland
| |
Collapse
|
9
|
Agglopoulou O, Gkrinia E, Bizaki-Vallaskangas A, Hajiioannou J, Bizakis I. Quality of Life in Patients With Well-Differentiated Thyroid Carcinoma After Total Thyroidectomy in Greece. Cureus 2024; 16:e53304. [PMID: 38435919 PMCID: PMC10906695 DOI: 10.7759/cureus.53304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/30/2024] [Indexed: 03/05/2024] Open
Abstract
INTRODUCTION Well-differentiated thyroid cancer is among the most common types of endocrine cancer. Despite its increasing prevalence, the prognosis of thyroid cancer is rather good, with a five-year survival rate ranging between 80% and 90%, depending on the histological type. Not only the post-treatment complications and the side effects of the lifelong medication but also the possibility of a recurrence may have a negative impact on the patient's quality of life (QoL). OBJECTIVE The aim of this study is to investigate the impact of total thyroidectomy on the QoL of patients with well-differentiated thyroid carcinoma. METHODS A prospective study was performed in patients who underwent total thyroidectomy due to well-differentiated thyroid carcinoma in the Otolaryngology-Head and Neck Surgery Department at the University Hospital of Larissa, Greece. The QoL was evaluated based on the "Quality of Life (Thyroid Version)" questionnaire. RESULTS One hundred patients participated in the study, with a mean age of 51.24±15.33 years. Of these, 63 (63%) were females and 37 (37%) were males. Social concerns, physical well-being, and psychological well-being presented a gradual positive alteration during the first 12 months after the surgery, with psychological well-being reporting the most significant progress of 15.3%. However, spiritual well-being appeared to decline over time. The younger patients progressively improved their physical, psychological, and mental well-being; however, the older patients showed an amelioration of their social skills. Female patients reported higher levels of spiritual well-being, whereas males developed better social skills. CONCLUSIONS In the long term, total thyroidectomy can ameliorate patients' physical status, psychological well-being, and social concerns. However, it might have a negative effect on their mental health during the first 12 months postoperatively. In addition, QoL is directly influenced by demographic characteristics such as age and gender.
Collapse
Affiliation(s)
- Olga Agglopoulou
- Otolaryngology-Head and Neck Surgery, University Hospital of Larissa, Larissa, GRC
| | - Eleni Gkrinia
- Otolaryngology-Head and Neck Surgery, University Hospital of Larissa, Larissa, GRC
| | - Argyro Bizaki-Vallaskangas
- Otolaryngology, Faculty of Medicine and Health Technology, University Hospital of Tampere, Tampere University, Tampere, FIN
| | - Jiannis Hajiioannou
- Otolaryngology-Head and Neck Surgery, University Hospital of Larissa, Larissa, GRC
| | - Ioannis Bizakis
- Otolaryngology-Head and Neck Surgery, Faculty of Medicine, University of Thessaly, Larissa, GRC
| |
Collapse
|
10
|
Zhao L, Hu T, Cai Y, Zhou T, Zhang W, Wu F, Zhang Y, Luo D. Preoperative risk stratification for patients with ≤ 1 cm papillary thyroid carcinomas based on preoperative blood inflammatory markers: construction of a dynamic predictive model. Front Endocrinol (Lausanne) 2023; 14:1254124. [PMID: 38189045 PMCID: PMC10767669 DOI: 10.3389/fendo.2023.1254124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/06/2023] [Accepted: 11/16/2023] [Indexed: 01/09/2024] Open
Abstract
Objective The aim of this study was to investigate the relationships and predictive value of preoperative peripheral blood inflammatory markers as a means by which to assess risk for patients with ≤ 1 cm papillary thyroid carcinomas (PTCs). In addition, a preoperative risk stratification predictive model was constructed and validated. Methods Clinical and pathologic data, as well as preoperative blood specimens, were collected from patients who underwent initial thyroid cancer surgery at the Hangzhou First People's Hospital, from January 2014 to January 2023. Risk assessment was performed based on postoperative pathology according to the 2015 ATA guidelines for recurrence risk stratification. Using univariate analysis and multivariate logistic regression, we identified independent risk factors associated with risk stratification. A predictive model was established and its discriminative and calibration abilities were validated. An independent validation dataset was used to verify the model, and the model was deployed as an online calculator. Results A total of 1326 patients were included in the study, with 1047 cases (79.0%) classified as low risk and 279 cases (21.0%) classified as intermediate to high risk. The modeling group consisted of 981 cases, through univariate analysis and multivariate logistic regression analysis, preoperative blood Neutrophil/Lymphocyte Ratio (NLR), gender, tumor diameter, and multifocality were identified as independent risk factors that distinguished between low and intermediate to high risk patients with ≤ 1 cm PTCs. The clinical predictive model exhibited an AUC of 0.785, specificity of 70.6%, and sensitivity of 75.8%. For the independent validation group of 345 patients, the AUC was 0.813, specificity was 83.8%, and sensitivity was 70.4%. The calibration curve and clinical decision curve indicate that the model demonstrates excellent calibration performance. Conclusion A dynamic clinical predictive model based on preoperative blood NLR and clinical information for patients with ≤ 1 cm PTCs was established. The model is useful for preoperative risk assessment of patients with ≤ 1 cm PTCs.
Collapse
Affiliation(s)
- Lingqian Zhao
- Zhejiang Chinese Medical University, Fourth Clinical Medical College, Hangzhou, Zhejiang, China
- Hangzhou First People’s Hospital, Department of Oncological Surgery, Hangzhou, Zhejiang, China
| | - Tao Hu
- Zhejiang Chinese Medical University, Fourth Clinical Medical College, Hangzhou, Zhejiang, China
- Hangzhou First People’s Hospital, Department of Oncological Surgery, Hangzhou, Zhejiang, China
| | - Yuan Cai
- Zhejiang Chinese Medical University, Fourth Clinical Medical College, Hangzhou, Zhejiang, China
- Hangzhou First People’s Hospital, Department of Oncological Surgery, Hangzhou, Zhejiang, China
| | - Tianhan Zhou
- Hangzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, The Department of General Surgery, Hangzhou, Zhejiang, China
| | - Wenhao Zhang
- The First Affiliated Hospital of Zhejiang Chinese Medicine University, Department of Urology1and Pathology2, Hangzhou, Zhejiang, China
| | - Fan Wu
- Hangzhou First People’s Hospital, Department of Oncological Surgery, Hangzhou, Zhejiang, China
| | - Yu Zhang
- Hangzhou First People’s Hospital, Department of Oncological Surgery, Hangzhou, Zhejiang, China
| | - Dingcun Luo
- Zhejiang Chinese Medical University, Fourth Clinical Medical College, Hangzhou, Zhejiang, China
- Hangzhou First People’s Hospital, Department of Oncological Surgery, Hangzhou, Zhejiang, China
| |
Collapse
|
11
|
Siraj AK, Parvathareddy SK, Al-Rasheed M, Annaiyappanaidu P, Siraj N, Lennartz M, Al-Sobhi SS, Al-Dayel F, Sauter G, Al-Kuraya KS. Loss of CDH16 expression is a strong independent predictor for lymph node metastasis in Middle Eastern papillary thyroid cancer. Sci Rep 2023; 13:18559. [PMID: 37899424 PMCID: PMC10613612 DOI: 10.1038/s41598-023-45882-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2023] [Accepted: 10/25/2023] [Indexed: 10/31/2023] Open
Abstract
Papillary Thyroid Cancer (PTC) is the most common type of thyroid cancer. The membrane-associated glycoprotein cadherin-16 (CDH16) plays a significant role in the embryonal development of thyroid follicles and cell adhesion. Previous studies have indicated a substantial downregulation of CDH16 in PTC. However, its role in Middle Eastern PTC has not been elucidated. We analyzed a tissue microarray comprising 1606 PTC and 240 normal thyroid tissues using immunohistochemistry to assess CDH16 expression and determine its clinico-pathological associations. We also conducted BRAF and TERT mutations analyses through Sanger sequencing. Disease-free survival (DFS) was assessed using Kaplan-Meier curves. CDH16 immunostaining was seen in 100% of normal thyroid tissues but only in 9.4% of PTC tissues (p < 0.0001). The loss of CDH16 expression was associated with aggressive PTC characteristics including bilaterality, multifocality, extrathyroidal extension, tall cell variant, lymph node metastasis (LNM) and distant metastasis. Additionally a correlation between loss of CDH16 expression and BRAF and TERT mutations was identified. Intriguingly, upon conducting multivariate logistic regression analysis, CDH16 was determined to be an independent predictor for LNM (Odds ratio = 2.46; 95% confidence interval = 1.60-3.79; p < 0.0001). Furthermore, CDH16 loss was associated with a shorter DFS (p = 0.0015). However, when we further subdivided CDH16 negative patients based on the co-existence of TERT and/or BRAF mutations, we found that patients with both CDH16 negative expression and TERT mutation exhibited the shortest DFS (p < 0.0001). In conclusion, our results suggest that CDH16 protein expression could serve as a valuable diagnostic tool for PTC. Furthermore, these findings demonstrate that the loss of CDH16 expression is an independent predictor of LNM and may contribute to the aggressiveness of PTC. Therefore, downregulation of CDH16 in PTC might be a potential target for designing novel therapeutic strategies to treat PTC.
Collapse
Affiliation(s)
- Abdul K Siraj
- Human Cancer Genomic Research, Research Centre, King Faisal Specialist Hospital and Research Centre, MBC#98-16, P.O. Box 3354, 11211, Riyadh, Saudi Arabia
| | - Sandeep Kumar Parvathareddy
- Human Cancer Genomic Research, Research Centre, King Faisal Specialist Hospital and Research Centre, MBC#98-16, P.O. Box 3354, 11211, Riyadh, Saudi Arabia
| | - Maha Al-Rasheed
- Human Cancer Genomic Research, Research Centre, King Faisal Specialist Hospital and Research Centre, MBC#98-16, P.O. Box 3354, 11211, Riyadh, Saudi Arabia
| | - Padmanaban Annaiyappanaidu
- Human Cancer Genomic Research, Research Centre, King Faisal Specialist Hospital and Research Centre, MBC#98-16, P.O. Box 3354, 11211, Riyadh, Saudi Arabia
| | - Nabil Siraj
- Human Cancer Genomic Research, Research Centre, King Faisal Specialist Hospital and Research Centre, MBC#98-16, P.O. Box 3354, 11211, Riyadh, Saudi Arabia
| | - Maximilian Lennartz
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Saif S Al-Sobhi
- Department of Surgery, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia
| | - Fouad Al-Dayel
- Department of Pathology, King Faisal Specialist Hospital and Research Centre, P.O. Box 3354, 11211, Riyadh, Saudi Arabia
| | - Guido Sauter
- Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - Khawla S Al-Kuraya
- Human Cancer Genomic Research, Research Centre, King Faisal Specialist Hospital and Research Centre, MBC#98-16, P.O. Box 3354, 11211, Riyadh, Saudi Arabia.
| |
Collapse
|
12
|
Li Y, Tian J, Jiang K, Wang Z, Gao S, Wei K, Yang A, Li Q. Risk factors and predictive model for recurrence in papillary thyroid carcinoma: a single-center retrospective cohort study based on 955 cases. Front Endocrinol (Lausanne) 2023; 14:1268282. [PMID: 37810888 PMCID: PMC10552524 DOI: 10.3389/fendo.2023.1268282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Accepted: 09/04/2023] [Indexed: 10/10/2023] Open
Abstract
Background The 2015 American Thyroid Association guidelines proposed recurrence risk stratification of differentiated thyroid carcinoma, including papillary thyroid carcinoma (PTC), but this stratification excluded non-initial treatment patients with worse outcomes. This study aimed to explore the potential risk factors for recurrence in PTC and develop a predictive model for both initial and non-initial treatment of patients with PTC. Methods A total of 955 patients were included in this study. Differences between the recurrence (-) and recurrence (+) groups were compared. The 955 patients were randomized into two groups: the training group (671 cases) and the validation group (284 cases). All variables were selected using the LASSO regression analysis. A nomogram was developed based on the results of the univariate and multivariate logistic regression analyses. The nomogram performance was evaluated using discrimination and calibration. Results Patients aged ≥55 years, extranodal extension (ENE), metastatic LN ratio (LNR) >0.5, and non-initial treatment were identified as potential risk factors for recurrence through LASSO regression and univariate and multivariate analyses. The receiver operating characteristic curve (ROC curve) showed high efficiency, with an area under the ROC curve (AUC) of 0.819 (95% confidence interval [CI], 0.729-0.909) and 0.818 (95% CI, 0.670-0.909) in the training and validation groups, respectively. The calibration curve indicated that the nomogram had a good consistency. Conclusion In patients with PTC, age ≥55 years, ENE, LNR >0.5, and non-initial treatment are potential risk factors for recurrence. The predictive model of recurrence was confirmed to be a practical and convenient tool for clinicians to accurately predict PTC recurrence.
Collapse
Affiliation(s)
- Yin Li
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China
- Department of Head and Neck Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China
| | - Jiahe Tian
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China
- Department of Head and Neck Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China
| | - Ke Jiang
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China
- Department of Head and Neck Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China
| | - Zhongyu Wang
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China
- Department of Head and Neck Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China
| | - Songbo Gao
- Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China
| | - Keyang Wei
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China
- Department of Head and Neck Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China
| | - Ankui Yang
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China
- Department of Head and Neck Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China
| | - Qiuli Li
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China
- Department of Head and Neck Surgery, Sun Yat-Sen University Cancer Center, Guangzhou, China
| |
Collapse
|
13
|
Zheng L, Dou JP, Han ZY, Liu FY, Yu J, Cheng ZG, Yu XL, Wang H, Cong ZB, Wang SR, Yu MA, Xu ZF, Che Y, Nan B, Liu C, Hao Y, Wang X, Liu Y, Zhou Y, Liang P. Microwave Ablation for Papillary Thyroid Microcarcinoma with and without US-detected Capsule Invasion: A Multicenter Prospective Cohort Study. Radiology 2023; 307:e220661. [PMID: 36880949 DOI: 10.1148/radiol.220661] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/08/2023]
Abstract
Background Microwave ablation (MWA) has achieved favorable results in the treatment of papillary thyroid microcarcinoma (PTMC) confined in glandular parenchyma. However, studies on the outcome of MWA for PTMC with US-detected capsular invasion remain unclarified in the literature. Purpose To compare the feasibility, effectiveness, and safety of MWA in the treatment of PTMC with and without US-detected capsular invasion. Materials and Methods Participants from 12 hospitals with a PTMC maximal diameter of 1 cm or less without US- or CT-detected lymph node metastasis (LNM) who planned to undergo MWA were enrolled in this prospective study between December 2019 and April 2021. All tumors were evaluated with preoperative US and were divided into those with and those without capsular invasion. The participants were observed until July 1, 2022. The primary end points, including technical success and disease progression, and the secondary end points, including treatment parameters, complications, and tumor shrinkage during follow-up, were compared between the two groups, and multivariable regression was performed. Results After exclusion, 461 participants (mean age, 43 years ± 11 [SD]; 337 women) were included: 83 with and 378 without capsular invasion. After one participant with capsular invasion aborted MWA because of technical failure, 82 participants with and 378 participants without capsular invasion (mean tumor volume, 0.1 mL ± 0.1 vs 0.1 mL ± 0.1; P = .07) were analyzed with a mean follow-up period of 20 months ± 4 (range, 12-25 months) and 21 months ± 4 (range, 11-26 months), respectively. In those with and those without capsular invasion, comparable technical success rates were achieved (99% [82 of 83] vs 100% [378 of 378], P = .18), with one and 11 complications, respectively (1% [one of 82] vs 3% [11 of 378], P = .38). There was no evidence of differences in disease progression (2% [one of 82] vs 1% [four of 378]; P = .82) or tumor shrinkage (mean, 97% ± 8 [SD] vs 96% ± 13; P = .58). Conclusion Microwave ablation was feasible in the treatment of papillary thyroid microcarcinoma with US-detected capsular invasion and showed comparable short-term efficacy with or without the presence of capsular invasion. © RSNA, 2023 Clinical trial registration no. NCT04197960 Supplemental material is available for this article.
Collapse
Affiliation(s)
- Lin Zheng
- From the Department of Interventional Ultrasound, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China (L.Z., J.P.D., Z.Y.H., F.Y.L., J.Y., Z.G.C., X.L.Y., P.L.); Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, China (H.W.); Department of Electrodiagnosis, the Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China (Z.B.C., X.W.); Department of Medical Ultrasound, Yantai Hospital of Shandong Wendeng Orthopaedics & Traumatology, Yantai, China (S.R.W., Y.L.); Department of Interventional Ultrasound Medicine, China-Japan Friendship Hospital, Beijing, China (M.A.Y.); First Department of Surgery, Hebei Hospital of Traditional Chinese Medicine, Shijiazhuang, China (Z.F.X., Y.Z.); First Affiliated Hospital of Dalian Medical University, Dalian, China (Y.C.); Department of Surgery, Beijing Jishuitan Hospital, Beijing, China (B.N.); Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, China (C.L.); and Department of Ultrasound, Mudanjiang Tumor Hospital, Mudanjiang, China (Y.H.)
| | - Jian-Ping Dou
- From the Department of Interventional Ultrasound, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China (L.Z., J.P.D., Z.Y.H., F.Y.L., J.Y., Z.G.C., X.L.Y., P.L.); Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, China (H.W.); Department of Electrodiagnosis, the Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China (Z.B.C., X.W.); Department of Medical Ultrasound, Yantai Hospital of Shandong Wendeng Orthopaedics & Traumatology, Yantai, China (S.R.W., Y.L.); Department of Interventional Ultrasound Medicine, China-Japan Friendship Hospital, Beijing, China (M.A.Y.); First Department of Surgery, Hebei Hospital of Traditional Chinese Medicine, Shijiazhuang, China (Z.F.X., Y.Z.); First Affiliated Hospital of Dalian Medical University, Dalian, China (Y.C.); Department of Surgery, Beijing Jishuitan Hospital, Beijing, China (B.N.); Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, China (C.L.); and Department of Ultrasound, Mudanjiang Tumor Hospital, Mudanjiang, China (Y.H.)
| | - Zhi-Yu Han
- From the Department of Interventional Ultrasound, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China (L.Z., J.P.D., Z.Y.H., F.Y.L., J.Y., Z.G.C., X.L.Y., P.L.); Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, China (H.W.); Department of Electrodiagnosis, the Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China (Z.B.C., X.W.); Department of Medical Ultrasound, Yantai Hospital of Shandong Wendeng Orthopaedics & Traumatology, Yantai, China (S.R.W., Y.L.); Department of Interventional Ultrasound Medicine, China-Japan Friendship Hospital, Beijing, China (M.A.Y.); First Department of Surgery, Hebei Hospital of Traditional Chinese Medicine, Shijiazhuang, China (Z.F.X., Y.Z.); First Affiliated Hospital of Dalian Medical University, Dalian, China (Y.C.); Department of Surgery, Beijing Jishuitan Hospital, Beijing, China (B.N.); Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, China (C.L.); and Department of Ultrasound, Mudanjiang Tumor Hospital, Mudanjiang, China (Y.H.)
| | - Fang-Yi Liu
- From the Department of Interventional Ultrasound, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China (L.Z., J.P.D., Z.Y.H., F.Y.L., J.Y., Z.G.C., X.L.Y., P.L.); Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, China (H.W.); Department of Electrodiagnosis, the Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China (Z.B.C., X.W.); Department of Medical Ultrasound, Yantai Hospital of Shandong Wendeng Orthopaedics & Traumatology, Yantai, China (S.R.W., Y.L.); Department of Interventional Ultrasound Medicine, China-Japan Friendship Hospital, Beijing, China (M.A.Y.); First Department of Surgery, Hebei Hospital of Traditional Chinese Medicine, Shijiazhuang, China (Z.F.X., Y.Z.); First Affiliated Hospital of Dalian Medical University, Dalian, China (Y.C.); Department of Surgery, Beijing Jishuitan Hospital, Beijing, China (B.N.); Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, China (C.L.); and Department of Ultrasound, Mudanjiang Tumor Hospital, Mudanjiang, China (Y.H.)
| | - Jie Yu
- From the Department of Interventional Ultrasound, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China (L.Z., J.P.D., Z.Y.H., F.Y.L., J.Y., Z.G.C., X.L.Y., P.L.); Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, China (H.W.); Department of Electrodiagnosis, the Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China (Z.B.C., X.W.); Department of Medical Ultrasound, Yantai Hospital of Shandong Wendeng Orthopaedics & Traumatology, Yantai, China (S.R.W., Y.L.); Department of Interventional Ultrasound Medicine, China-Japan Friendship Hospital, Beijing, China (M.A.Y.); First Department of Surgery, Hebei Hospital of Traditional Chinese Medicine, Shijiazhuang, China (Z.F.X., Y.Z.); First Affiliated Hospital of Dalian Medical University, Dalian, China (Y.C.); Department of Surgery, Beijing Jishuitan Hospital, Beijing, China (B.N.); Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, China (C.L.); and Department of Ultrasound, Mudanjiang Tumor Hospital, Mudanjiang, China (Y.H.)
| | - Zhi-Gang Cheng
- From the Department of Interventional Ultrasound, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China (L.Z., J.P.D., Z.Y.H., F.Y.L., J.Y., Z.G.C., X.L.Y., P.L.); Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, China (H.W.); Department of Electrodiagnosis, the Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China (Z.B.C., X.W.); Department of Medical Ultrasound, Yantai Hospital of Shandong Wendeng Orthopaedics & Traumatology, Yantai, China (S.R.W., Y.L.); Department of Interventional Ultrasound Medicine, China-Japan Friendship Hospital, Beijing, China (M.A.Y.); First Department of Surgery, Hebei Hospital of Traditional Chinese Medicine, Shijiazhuang, China (Z.F.X., Y.Z.); First Affiliated Hospital of Dalian Medical University, Dalian, China (Y.C.); Department of Surgery, Beijing Jishuitan Hospital, Beijing, China (B.N.); Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, China (C.L.); and Department of Ultrasound, Mudanjiang Tumor Hospital, Mudanjiang, China (Y.H.)
| | - Xiao-Ling Yu
- From the Department of Interventional Ultrasound, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China (L.Z., J.P.D., Z.Y.H., F.Y.L., J.Y., Z.G.C., X.L.Y., P.L.); Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, China (H.W.); Department of Electrodiagnosis, the Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China (Z.B.C., X.W.); Department of Medical Ultrasound, Yantai Hospital of Shandong Wendeng Orthopaedics & Traumatology, Yantai, China (S.R.W., Y.L.); Department of Interventional Ultrasound Medicine, China-Japan Friendship Hospital, Beijing, China (M.A.Y.); First Department of Surgery, Hebei Hospital of Traditional Chinese Medicine, Shijiazhuang, China (Z.F.X., Y.Z.); First Affiliated Hospital of Dalian Medical University, Dalian, China (Y.C.); Department of Surgery, Beijing Jishuitan Hospital, Beijing, China (B.N.); Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, China (C.L.); and Department of Ultrasound, Mudanjiang Tumor Hospital, Mudanjiang, China (Y.H.)
| | - Hui Wang
- From the Department of Interventional Ultrasound, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China (L.Z., J.P.D., Z.Y.H., F.Y.L., J.Y., Z.G.C., X.L.Y., P.L.); Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, China (H.W.); Department of Electrodiagnosis, the Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China (Z.B.C., X.W.); Department of Medical Ultrasound, Yantai Hospital of Shandong Wendeng Orthopaedics & Traumatology, Yantai, China (S.R.W., Y.L.); Department of Interventional Ultrasound Medicine, China-Japan Friendship Hospital, Beijing, China (M.A.Y.); First Department of Surgery, Hebei Hospital of Traditional Chinese Medicine, Shijiazhuang, China (Z.F.X., Y.Z.); First Affiliated Hospital of Dalian Medical University, Dalian, China (Y.C.); Department of Surgery, Beijing Jishuitan Hospital, Beijing, China (B.N.); Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, China (C.L.); and Department of Ultrasound, Mudanjiang Tumor Hospital, Mudanjiang, China (Y.H.)
| | - Zhi-Bin Cong
- From the Department of Interventional Ultrasound, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China (L.Z., J.P.D., Z.Y.H., F.Y.L., J.Y., Z.G.C., X.L.Y., P.L.); Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, China (H.W.); Department of Electrodiagnosis, the Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China (Z.B.C., X.W.); Department of Medical Ultrasound, Yantai Hospital of Shandong Wendeng Orthopaedics & Traumatology, Yantai, China (S.R.W., Y.L.); Department of Interventional Ultrasound Medicine, China-Japan Friendship Hospital, Beijing, China (M.A.Y.); First Department of Surgery, Hebei Hospital of Traditional Chinese Medicine, Shijiazhuang, China (Z.F.X., Y.Z.); First Affiliated Hospital of Dalian Medical University, Dalian, China (Y.C.); Department of Surgery, Beijing Jishuitan Hospital, Beijing, China (B.N.); Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, China (C.L.); and Department of Ultrasound, Mudanjiang Tumor Hospital, Mudanjiang, China (Y.H.)
| | - Shu-Rong Wang
- From the Department of Interventional Ultrasound, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China (L.Z., J.P.D., Z.Y.H., F.Y.L., J.Y., Z.G.C., X.L.Y., P.L.); Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, China (H.W.); Department of Electrodiagnosis, the Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China (Z.B.C., X.W.); Department of Medical Ultrasound, Yantai Hospital of Shandong Wendeng Orthopaedics & Traumatology, Yantai, China (S.R.W., Y.L.); Department of Interventional Ultrasound Medicine, China-Japan Friendship Hospital, Beijing, China (M.A.Y.); First Department of Surgery, Hebei Hospital of Traditional Chinese Medicine, Shijiazhuang, China (Z.F.X., Y.Z.); First Affiliated Hospital of Dalian Medical University, Dalian, China (Y.C.); Department of Surgery, Beijing Jishuitan Hospital, Beijing, China (B.N.); Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, China (C.L.); and Department of Ultrasound, Mudanjiang Tumor Hospital, Mudanjiang, China (Y.H.)
| | - Ming-An Yu
- From the Department of Interventional Ultrasound, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China (L.Z., J.P.D., Z.Y.H., F.Y.L., J.Y., Z.G.C., X.L.Y., P.L.); Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, China (H.W.); Department of Electrodiagnosis, the Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China (Z.B.C., X.W.); Department of Medical Ultrasound, Yantai Hospital of Shandong Wendeng Orthopaedics & Traumatology, Yantai, China (S.R.W., Y.L.); Department of Interventional Ultrasound Medicine, China-Japan Friendship Hospital, Beijing, China (M.A.Y.); First Department of Surgery, Hebei Hospital of Traditional Chinese Medicine, Shijiazhuang, China (Z.F.X., Y.Z.); First Affiliated Hospital of Dalian Medical University, Dalian, China (Y.C.); Department of Surgery, Beijing Jishuitan Hospital, Beijing, China (B.N.); Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, China (C.L.); and Department of Ultrasound, Mudanjiang Tumor Hospital, Mudanjiang, China (Y.H.)
| | - Zhi-Feng Xu
- From the Department of Interventional Ultrasound, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China (L.Z., J.P.D., Z.Y.H., F.Y.L., J.Y., Z.G.C., X.L.Y., P.L.); Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, China (H.W.); Department of Electrodiagnosis, the Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China (Z.B.C., X.W.); Department of Medical Ultrasound, Yantai Hospital of Shandong Wendeng Orthopaedics & Traumatology, Yantai, China (S.R.W., Y.L.); Department of Interventional Ultrasound Medicine, China-Japan Friendship Hospital, Beijing, China (M.A.Y.); First Department of Surgery, Hebei Hospital of Traditional Chinese Medicine, Shijiazhuang, China (Z.F.X., Y.Z.); First Affiliated Hospital of Dalian Medical University, Dalian, China (Y.C.); Department of Surgery, Beijing Jishuitan Hospital, Beijing, China (B.N.); Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, China (C.L.); and Department of Ultrasound, Mudanjiang Tumor Hospital, Mudanjiang, China (Y.H.)
| | - Ying Che
- From the Department of Interventional Ultrasound, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China (L.Z., J.P.D., Z.Y.H., F.Y.L., J.Y., Z.G.C., X.L.Y., P.L.); Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, China (H.W.); Department of Electrodiagnosis, the Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China (Z.B.C., X.W.); Department of Medical Ultrasound, Yantai Hospital of Shandong Wendeng Orthopaedics & Traumatology, Yantai, China (S.R.W., Y.L.); Department of Interventional Ultrasound Medicine, China-Japan Friendship Hospital, Beijing, China (M.A.Y.); First Department of Surgery, Hebei Hospital of Traditional Chinese Medicine, Shijiazhuang, China (Z.F.X., Y.Z.); First Affiliated Hospital of Dalian Medical University, Dalian, China (Y.C.); Department of Surgery, Beijing Jishuitan Hospital, Beijing, China (B.N.); Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, China (C.L.); and Department of Ultrasound, Mudanjiang Tumor Hospital, Mudanjiang, China (Y.H.)
| | - Bai Nan
- From the Department of Interventional Ultrasound, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China (L.Z., J.P.D., Z.Y.H., F.Y.L., J.Y., Z.G.C., X.L.Y., P.L.); Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, China (H.W.); Department of Electrodiagnosis, the Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China (Z.B.C., X.W.); Department of Medical Ultrasound, Yantai Hospital of Shandong Wendeng Orthopaedics & Traumatology, Yantai, China (S.R.W., Y.L.); Department of Interventional Ultrasound Medicine, China-Japan Friendship Hospital, Beijing, China (M.A.Y.); First Department of Surgery, Hebei Hospital of Traditional Chinese Medicine, Shijiazhuang, China (Z.F.X., Y.Z.); First Affiliated Hospital of Dalian Medical University, Dalian, China (Y.C.); Department of Surgery, Beijing Jishuitan Hospital, Beijing, China (B.N.); Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, China (C.L.); and Department of Ultrasound, Mudanjiang Tumor Hospital, Mudanjiang, China (Y.H.)
| | - Cun Liu
- From the Department of Interventional Ultrasound, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China (L.Z., J.P.D., Z.Y.H., F.Y.L., J.Y., Z.G.C., X.L.Y., P.L.); Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, China (H.W.); Department of Electrodiagnosis, the Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China (Z.B.C., X.W.); Department of Medical Ultrasound, Yantai Hospital of Shandong Wendeng Orthopaedics & Traumatology, Yantai, China (S.R.W., Y.L.); Department of Interventional Ultrasound Medicine, China-Japan Friendship Hospital, Beijing, China (M.A.Y.); First Department of Surgery, Hebei Hospital of Traditional Chinese Medicine, Shijiazhuang, China (Z.F.X., Y.Z.); First Affiliated Hospital of Dalian Medical University, Dalian, China (Y.C.); Department of Surgery, Beijing Jishuitan Hospital, Beijing, China (B.N.); Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, China (C.L.); and Department of Ultrasound, Mudanjiang Tumor Hospital, Mudanjiang, China (Y.H.)
| | - Ying Hao
- From the Department of Interventional Ultrasound, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China (L.Z., J.P.D., Z.Y.H., F.Y.L., J.Y., Z.G.C., X.L.Y., P.L.); Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, China (H.W.); Department of Electrodiagnosis, the Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China (Z.B.C., X.W.); Department of Medical Ultrasound, Yantai Hospital of Shandong Wendeng Orthopaedics & Traumatology, Yantai, China (S.R.W., Y.L.); Department of Interventional Ultrasound Medicine, China-Japan Friendship Hospital, Beijing, China (M.A.Y.); First Department of Surgery, Hebei Hospital of Traditional Chinese Medicine, Shijiazhuang, China (Z.F.X., Y.Z.); First Affiliated Hospital of Dalian Medical University, Dalian, China (Y.C.); Department of Surgery, Beijing Jishuitan Hospital, Beijing, China (B.N.); Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, China (C.L.); and Department of Ultrasound, Mudanjiang Tumor Hospital, Mudanjiang, China (Y.H.)
| | - Xue Wang
- From the Department of Interventional Ultrasound, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China (L.Z., J.P.D., Z.Y.H., F.Y.L., J.Y., Z.G.C., X.L.Y., P.L.); Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, China (H.W.); Department of Electrodiagnosis, the Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China (Z.B.C., X.W.); Department of Medical Ultrasound, Yantai Hospital of Shandong Wendeng Orthopaedics & Traumatology, Yantai, China (S.R.W., Y.L.); Department of Interventional Ultrasound Medicine, China-Japan Friendship Hospital, Beijing, China (M.A.Y.); First Department of Surgery, Hebei Hospital of Traditional Chinese Medicine, Shijiazhuang, China (Z.F.X., Y.Z.); First Affiliated Hospital of Dalian Medical University, Dalian, China (Y.C.); Department of Surgery, Beijing Jishuitan Hospital, Beijing, China (B.N.); Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, China (C.L.); and Department of Ultrasound, Mudanjiang Tumor Hospital, Mudanjiang, China (Y.H.)
| | - Ying Liu
- From the Department of Interventional Ultrasound, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China (L.Z., J.P.D., Z.Y.H., F.Y.L., J.Y., Z.G.C., X.L.Y., P.L.); Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, China (H.W.); Department of Electrodiagnosis, the Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China (Z.B.C., X.W.); Department of Medical Ultrasound, Yantai Hospital of Shandong Wendeng Orthopaedics & Traumatology, Yantai, China (S.R.W., Y.L.); Department of Interventional Ultrasound Medicine, China-Japan Friendship Hospital, Beijing, China (M.A.Y.); First Department of Surgery, Hebei Hospital of Traditional Chinese Medicine, Shijiazhuang, China (Z.F.X., Y.Z.); First Affiliated Hospital of Dalian Medical University, Dalian, China (Y.C.); Department of Surgery, Beijing Jishuitan Hospital, Beijing, China (B.N.); Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, China (C.L.); and Department of Ultrasound, Mudanjiang Tumor Hospital, Mudanjiang, China (Y.H.)
| | - Ying Zhou
- From the Department of Interventional Ultrasound, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China (L.Z., J.P.D., Z.Y.H., F.Y.L., J.Y., Z.G.C., X.L.Y., P.L.); Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, China (H.W.); Department of Electrodiagnosis, the Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China (Z.B.C., X.W.); Department of Medical Ultrasound, Yantai Hospital of Shandong Wendeng Orthopaedics & Traumatology, Yantai, China (S.R.W., Y.L.); Department of Interventional Ultrasound Medicine, China-Japan Friendship Hospital, Beijing, China (M.A.Y.); First Department of Surgery, Hebei Hospital of Traditional Chinese Medicine, Shijiazhuang, China (Z.F.X., Y.Z.); First Affiliated Hospital of Dalian Medical University, Dalian, China (Y.C.); Department of Surgery, Beijing Jishuitan Hospital, Beijing, China (B.N.); Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, China (C.L.); and Department of Ultrasound, Mudanjiang Tumor Hospital, Mudanjiang, China (Y.H.)
| | - Ping Liang
- From the Department of Interventional Ultrasound, Chinese PLA General Hospital, No. 28 Fuxing Road, Haidian District, Beijing 100853, China (L.Z., J.P.D., Z.Y.H., F.Y.L., J.Y., Z.G.C., X.L.Y., P.L.); Department of Ultrasound, China-Japan Union Hospital of Jilin University, Changchun, China (H.W.); Department of Electrodiagnosis, the Affiliated Hospital to Changchun University of Traditional Chinese Medicine, Changchun, China (Z.B.C., X.W.); Department of Medical Ultrasound, Yantai Hospital of Shandong Wendeng Orthopaedics & Traumatology, Yantai, China (S.R.W., Y.L.); Department of Interventional Ultrasound Medicine, China-Japan Friendship Hospital, Beijing, China (M.A.Y.); First Department of Surgery, Hebei Hospital of Traditional Chinese Medicine, Shijiazhuang, China (Z.F.X., Y.Z.); First Affiliated Hospital of Dalian Medical University, Dalian, China (Y.C.); Department of Surgery, Beijing Jishuitan Hospital, Beijing, China (B.N.); Department of Ultrasound, Central Hospital Affiliated to Shandong First Medical University, Jinan, China (C.L.); and Department of Ultrasound, Mudanjiang Tumor Hospital, Mudanjiang, China (Y.H.)
| |
Collapse
|
14
|
Wang Y, Zheng J, Hu X, Chang Q, Qiao Y, Yao X, Zhou X. A retrospective study of papillary thyroid carcinoma: Hashimoto's thyroiditis as a protective biomarker for lymph node metastasis. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY 2023; 49:560-567. [PMID: 36404253 DOI: 10.1016/j.ejso.2022.11.014] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2022] [Revised: 11/02/2022] [Accepted: 11/07/2022] [Indexed: 11/13/2022]
Abstract
PURPOSE There is approximately 10%-50% of papillary thyroid carcinoma (PTC) patients with Hashimoto's thyroiditis (HT). In this research, we sought to better understand the role of HT in PTC progression as well as lymph node metastasis. METHODS It is a retrospective and cross-sectional study, and 4131 PTC patients who underwent thyroidectomy were finally enrolled. Chi-square test, univariate and multivariate logistic regression analyses were employed to evaluate both the risk factors and the critical roles of HT during PTC metastasis. RESULT In this cohort, 1555 patients (37.6%) were diagnosed with HT. According to multivariate analysis, male sex, high levels of TG and TPOAb, tumor extrathyroidal extension, maximum diameter >1 cm, and multifocality were independent risk factors for both central lymph node metastasis (CLNM) and lateral lymph node metastasis (LLNM). In addition, age <55 years and smoking were risk factors for CLNM, while CLNM was one of the risk factors for LLNM. Furthermore, HT was suggested a valuable protective factor for both CLNM and LLNM. In patients with HT, the total number of central lymph nodes was higher, while the positive rate was lower. Compared with those without HT, age and sex did not predict CLNM and LLNM in patients with HT. CONCLUSION HT is considered a protective factor for both CLNM and LLNM in PTC. For patients with HT, surgeons should pay more attention to the preservation of parathyroid gland and the protection of recurrent laryngeal nerve due to less lymph node metastasis. Otherwise, radical operation is highly recommended.
Collapse
Affiliation(s)
- Yu Wang
- Department of Maxillofacial and Otorhinolaryngological Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
| | - Jianwei Zheng
- Department of Maxillofacial and Otorhinolaryngological Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
| | - Xiaomeng Hu
- Department of Maxillofacial and Otorhinolaryngological Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
| | - Qing Chang
- Department of Maxillofacial and Otorhinolaryngological Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
| | - Yu Qiao
- Department of Maxillofacial and Otorhinolaryngological Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
| | - Xiaofeng Yao
- Department of Maxillofacial and Otorhinolaryngological Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
| | - Xuan Zhou
- Department of Maxillofacial and Otorhinolaryngological Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
| |
Collapse
|
15
|
Xie R, Chen W, Lv Y, Xu D, Huang D, Zhou T, Zhang S, Xiong C, Yu J. Overexpressed ZC3H13 suppresses papillary thyroid carcinoma growth through m6A modification-mediated IQGAP1 degradation. J Formos Med Assoc 2023:S0929-6646(22)00477-6. [PMID: 36739231 DOI: 10.1016/j.jfma.2022.12.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2022] [Revised: 12/12/2022] [Accepted: 12/28/2022] [Indexed: 02/05/2023]
Abstract
PURPOSE The purpose of this study was to clarify the effect of ZC3H13 on the growth of papillary thyroid carcinoma (PTC). METHODS Firstly, we used qRT-PCR and Western blot to compare the difference in the expression of ZC3H13 between normal thyroid epithelial cells and PTC cell lines. Then, ZC3H13 overexpression/knockout thyroid cancer cells were constructed by lentivirus transfection, and the effects of overexpression of ZC3H13 on the proliferation, migration and invasion of PTC cells were detected by CCK8 and transwell experiments. Lastly, MeRIP-qPCR, RIP and o Actinomycin D were used to verify that ZC3H13 regulated the expression of downstream target gene IQGAP1 through m6A modification. RESULTS ZC3H13 expression was decreased in PTC cell lines BCPAP, KTC-1, k1, HTH83, and TPC-1. Proliferation, invasion, and migration of PTC cells were inhibited by overexpressed ZC3H13 but increased by knockdown of ZC3H13. IQGAP1 expression was suppressed by ZC3H13 overexpression but enhanced by ZC3H13 knockdown. In ZC3H13-overexpressed PTC cells, the m6A level of IQGAP1 mRNA was increased, and the IQGAP1 mRNA expression was decreased with the increasing time of Actinomycin D treatment. YTHDF2 enriched more IQGAP1 mRNA than IgG and knockdown of YTHDF2 reversed the effect of ZC3H13 overexpression on IQGAP1 mRNA stability. The xenograft tumor experiment in nude mice confirmed that the overexpression of ZC3H13 inhibited tumor growth, while overexpression of IQGAP1 could reverse the inhibitory effect of ZC3H13 overexpression on tumor growth. CONCLUSION ZC3H13 mediates IQGAP1 mRNA degradation by promoting m6A modification of IQGAP1 mRNA, this provides a prospective therapeutic target for PTC.
Collapse
Affiliation(s)
- Rong Xie
- Department of Thyroid Surgery, Hongjiaozhou Branch of the Second Affiliated Hospital of Nanchang University, Xuefu Avenue, Honggutan District, Nanchang 330006, Jiangxi, China
| | - Wanzhi Chen
- Department of Thyroid Surgery, Hongjiaozhou Branch of the Second Affiliated Hospital of Nanchang University, Xuefu Avenue, Honggutan District, Nanchang 330006, Jiangxi, China
| | - Yunxia Lv
- Department of Thyroid Surgery, Hongjiaozhou Branch of the Second Affiliated Hospital of Nanchang University, Xuefu Avenue, Honggutan District, Nanchang 330006, Jiangxi, China
| | - Debin Xu
- Department of Thyroid Surgery, Hongjiaozhou Branch of the Second Affiliated Hospital of Nanchang University, Xuefu Avenue, Honggutan District, Nanchang 330006, Jiangxi, China
| | - Da Huang
- Department of Thyroid Surgery, Hongjiaozhou Branch of the Second Affiliated Hospital of Nanchang University, Xuefu Avenue, Honggutan District, Nanchang 330006, Jiangxi, China
| | - Tao Zhou
- Department of Thyroid Surgery, Hongjiaozhou Branch of the Second Affiliated Hospital of Nanchang University, Xuefu Avenue, Honggutan District, Nanchang 330006, Jiangxi, China
| | - Shuyong Zhang
- Department of Thyroid Surgery, Hongjiaozhou Branch of the Second Affiliated Hospital of Nanchang University, Xuefu Avenue, Honggutan District, Nanchang 330006, Jiangxi, China
| | - Chengfeng Xiong
- Department of Thyroid Surgery, Hongjiaozhou Branch of the Second Affiliated Hospital of Nanchang University, Xuefu Avenue, Honggutan District, Nanchang 330006, Jiangxi, China
| | - Jichun Yu
- Department of Thyroid Surgery, Hongjiaozhou Branch of the Second Affiliated Hospital of Nanchang University, Xuefu Avenue, Honggutan District, Nanchang 330006, Jiangxi, China.
| |
Collapse
|
16
|
Identification of potential biomarkers for papillary thyroid carcinoma by comprehensive bioinformatics analysis. Mol Cell Biochem 2023:10.1007/s11010-022-04606-x. [PMID: 36635603 DOI: 10.1007/s11010-022-04606-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2021] [Accepted: 10/28/2022] [Indexed: 01/14/2023]
Abstract
To perform bioinformatics analysis on the papillary thyroid carcinoma (PTC) gene chip dataset to explore new biological markers for PTC. The gene expression profiles of GSE3467 and GSE6004 chip data were collected by GEO2R, and the differentially expressed genes (DEGs) were selected for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Protein-protein interaction (PPI) relationship analysis was achieved using STRING, and the hub genes were obtained using the Cytoscape software. GEPIA was used to validate the expressions of the hub genes in the normal and tumor tissues and to conduct survival analyses. Pertinent genetic pathology results were fetched using the HPA database. Finally, the key genes were clinically verified by reverse transcription-polymerase chain reaction. 97 genes were jointly up-regulated and 107 genes were jointly down-regulated in GSE3467 and GSE6004. GO function enrichment analysis revealed that the DEGs were involved in the regulation of calcium ion transport into cytosol, integrin binding, and cell adhesion molecule binding. KEGG pathway enrichment analysis indicated that the DEGs were chiefly associated with thyroid cancer and non-small cell lung cancer. According to the PPI network, 30 key target genes were identified. Only the expressions of ANK2, TLE1, and TCF4 matched between the normal and tumor tissues, and were associated with disease prognosis. When compared with the normal thyroid tissues, the protein and mRNA expressions of ANK2, TLE1, and TCF4 were down-regulated in PTC. Significant differences exist in overall gene expression between the thyroid tissues of patients with PTC and those of healthy people. Furthermore, the differential genes ANK2, TLE1, and TCF4 are expected to be reliable molecular markers for the mechanism study and diagnosis of PTC.
Collapse
|
17
|
Identification of R-Spondin Gene Signature Predictive of Metastatic Progression in BRAFV 600E-Positive Papillary Thyroid Cancer. Cells 2022; 12:cells12010139. [PMID: 36611933 PMCID: PMC9818556 DOI: 10.3390/cells12010139] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2022] [Revised: 12/19/2022] [Accepted: 12/22/2022] [Indexed: 12/31/2022] Open
Abstract
Papillary thyroid carcinoma (PTC) is the most common malignancy of the thyroid gland and early stages are curable. However, a subset of PTCs shows an unusually aggressive phenotype with extensive lymph node metastasis and higher incidence of locoregional recurrence. In this study, we investigated a large cohort of PTC cases with an unusual aggressive phenotype using a high-throughput RNA sequencing (RNA-Seq) to identify differentially regulated genes associated with metastatic PTC. All metastatic PTC with mutated BRAF (V600E) but not BRAF wild-type expressed an up-regulation of R-Spondin Protein 4 (RSPO4) concomitant with an upregulation of genes involved in focal adhesion and cell-extracellular matrix signaling. Further immunohistochemistry validation confirmed the upregulation of these target genes in metastatic PTC cases. Preclinical studies using established PTC cell lines support that RSPO4 overexpression is associated with BRAF V600E mutation and is a critical upstream event that promote activation of kinases of focal adhesion signaling known to drive cancer cell locomotion and invasion. This finding opens up the potential of co-targeting B-Raf, RSPO and focal adhesion proteins as a pharmacological approach for aggressive BRAF V600E PTC.
Collapse
|
18
|
Chung SR, Baek JH, Rho YH, Choi YJ, Sung TY, Song DE, Kim TY, Lee JH. Sonographic Diagnosis of Cervical Lymph Node Metastasis in Patients with Thyroid Cancer and Comparison of European and Korean Guidelines for Stratifying the Risk of Malignant Lymph Node. Korean J Radiol 2022; 23:1102-1111. [PMID: 36126955 PMCID: PMC9614289 DOI: 10.3348/kjr.2022.0358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2021] [Revised: 08/11/2022] [Accepted: 08/18/2022] [Indexed: 12/24/2022] Open
Abstract
OBJECTIVE To evaluate the ultrasonography (US) features for diagnosing metastasis in cervical lymph nodes (LNs) in patients with thyroid cancer and compare the US classification of risk of LN metastasis between European and Korean guidelines. MATERIALS AND METHODS From January 2014 to December 2018, US-guided fine-needle aspiration was performed on 836 LNs from 714 patients for the preoperative nodal staging of thyroid cancer. The US features of LNs were retrospectively reviewed for the following features: size, presence of hilum, margin, orientation, cystic change, punctate echogenic foci (PEF), large echogenic foci, eccentric cortical thickening, abnormal vascularity, and cortical hyperechogenicity. A multiple logistic regression analysis was performed to identify the independent US features for the diagnosis of metastatic LNs. The diagnostic performance of independent US features was subsequently evaluated. LNs were categorized according to the Korean Thyroid Imaging Reporting and Data System (K-TIRADS) and European Thyroid Association (ETA) guidelines, and the correlation between the two sets of classifications was assessed. RESULTS Absence of the hilum, presence of cystic changes, PEF, abnormal vascularity, and cortical hyperechogenicity were independent US features of metastatic LNs. Cystic changes, PEF, abnormal vascularity, and cortical hyperechogenicity showed high specificity (86.8%-99.6%). The absence of the hilum had the highest sensitivity yet low specificity (66.4%). When LNs were classified according to the ETA guidelines and K-TIRADS, they yielded similar categorizations of malignancy risks and were strongly correlated (Spearman coefficient, 0.9766 [95% confidence interval, 0.973-0.979]). According to the ETA guidelines, 9.8% (82/836) of LNs were classified as "not specified." CONCLUSION Absence of hilum, cystic changes, PEF, abnormal vascularity, and cortical hyperechogenicity were independent US features suggestive of metastatic LNs in thyroid cancer. Both K-TIRADS and the ETA guidelines provided similar risk stratification for metastatic LNs with a high correlation; however, the ETA guidelines failed to classify 9.8% of LNs into a specific risk stratum. These results may provide a basis for revising LN classification in future guidelines.
Collapse
Affiliation(s)
- Sae Rom Chung
- Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | - Jung Hwan Baek
- Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | - Yun Hwa Rho
- Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | - Young Jun Choi
- Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | - Tae-Yon Sung
- Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | - Dong Eun Song
- Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | - Tae Yong Kim
- Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| | - Jeong Hyun Lee
- Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
| |
Collapse
|
19
|
Peng C, Yi D, Zhou Y, Yao J, Chen B, Yang C, Xu D. Differential diagnosis of non-diffuse primary thyroid lymphoma and papillary thyroid carcinoma by ultrasound combined with computed tomography. BMC Cancer 2022; 22:938. [PMID: 36042430 PMCID: PMC9429725 DOI: 10.1186/s12885-022-10035-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Accepted: 08/23/2022] [Indexed: 12/02/2022] Open
Abstract
Background Primary thyroid lymphoma (PTL) and papillary thyroid carcinoma (PTC) are both thyroid malignancies, but their therapeutic methods and prognosis are different. This study aims to explore their sonographic and computed tomography(CT)features, and to improve the early diagnosis rate. Methods The clinical and imaging data of 50 patients with non-diffuse PTL and 100 patients with PTC confirmed by pathology were retrospectively analysed. Results Of the 150 patients, from the perspective of clinical data, between non-diffuse PTL and PTC patients existed significant difference in age, maximum diameter of nodule, asymmetric enlargement and Hashimoto’s thyroiditis (P < 0.001), but not in gender ratio, echo texture, cystic change and anteroposterior-to-transverse ratio (P > 0.05). With respect to sonographic feature, non-diffuse PTL patients had a higher proportion than PTC patients in markedly hypoechoic, internal linear echogenic strands, posterior echo enhancement, rich vascularity, lack of calcification and homogeneous enhancement, with statistically significant difference (P < 0.05), while PTC patients had a higher proportion than non-diffuse PTL patients in irregular border, circumscribed margin, capsular invasion and significant enhancement, with statistically significant difference (P < 0.001). With respect to CT feature, non-diffuse PTL patients were significantly different from PTC patients in the non-contrast CT value mean, venous phase CT value mean, enhanced intensity and homogeneity of nodules (P < 0.05). Multivariate logistic regression analysis showed that age (OR = 1.226, 95%CI:1.056 ~ 1.423, P = 0.007), posterior echo enhancement (OR = 51.152, 95%CI: 2.934 ~ 891.738, P = 0.007), lack of calcification (OR = 0.013, 95%CI: 0.000 ~ 0.400, P = 0.013) and homogeneous enhancement (OR = 0.020, 95%CI: 0.001 ~ 0.507, P = 0.018) were independent risk factors. Conclusions Sonographic and CT features of the presence of posterior echo enhancement, lack of calcification and homogeneous enhancement were valuable to distinguishing non-diffuse PTL from PTC.
Collapse
Affiliation(s)
- Chanjuan Peng
- Department of Ultrasound, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), No.1 East Banshan 7 Road, Gongshu District, Hangzhou, 310022, China.,Institute of Basic Medicine and Cancer (IBMC), Chinese Academy Of Sciences, Hangzhou, 310022, China
| | - Dan Yi
- Department of Ultrasound, Shaoxing People's Hospital, Hangzhou, 312000, China
| | - Ying Zhou
- Department of Surgery, Hebei Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang, 050000, China
| | - Jincao Yao
- Department of Ultrasound, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), No.1 East Banshan 7 Road, Gongshu District, Hangzhou, 310022, China.,Institute of Basic Medicine and Cancer (IBMC), Chinese Academy Of Sciences, Hangzhou, 310022, China
| | - Bo Chen
- Department of Radiology, Shaoxing People's Hospital, Shaoxing, 312000, China
| | - Chen Yang
- Department of Ultrasound, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), No.1 East Banshan 7 Road, Gongshu District, Hangzhou, 310022, China. .,Institute of Basic Medicine and Cancer (IBMC), Chinese Academy Of Sciences, Hangzhou, 310022, China.
| | - Dong Xu
- Department of Ultrasound, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), No.1 East Banshan 7 Road, Gongshu District, Hangzhou, 310022, China. .,Institute of Basic Medicine and Cancer (IBMC), Chinese Academy Of Sciences, Hangzhou, 310022, China. .,Key Laboratory of Head & Neck Cancer Translational Research of Zhejiang Province, Hangzhou, 310022, China. .,Zhejiang Provincial Research Center for Cancer Intelligent Diagnosis and Molecular Technology, Hangzhou, 310022, China.
| |
Collapse
|
20
|
Guo Q, Sun C, Chang Q, Wang Y, Chen Y, Wang Q, Li Z, Niu L. Contrast-enhanced ultrasound-based nomogram for predicting malignant involvements among sonographically indeterminate/suspicious cervical lymph nodes in patients with differentiated thyroid carcinoma. ULTRASOUND IN MEDICINE & BIOLOGY 2022; 48:1579-1589. [PMID: 35577662 DOI: 10.1016/j.ultrasmedbio.2022.04.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/15/2021] [Revised: 03/03/2022] [Accepted: 04/11/2022] [Indexed: 06/15/2023]
Abstract
This prospective study was aimed at assessing the value of nomograms based on conventional and contrast-enhanced ultrasound (CEUS) features in the pre-operative diagnosis of sonographically indeterminate/suspicious lymph node metastasis (LNM) in patients with differentiated thyroid carcinoma (DTC). A total of 72 cervical LNs from 47 patients with DTC from January to June 2018 were included in the primary data set, and 30 LNs from 15 patients with DTC from July to August 2018 were included in the external validation data set. The LNs of the included patients were preoperatively evaluated by conventional ultrasound (US) and CEUS. Each included LN was labeled by puncture localization with carbon nanoparticle suspension injection (Canalin) under US guidance and dissected separately to ensure the one-to-one correspondence between ultrasonic features and pathology status. Univariate logistic regression analysis was used to identify risk factors for LNM. A nomogram was used to construct a prediction model for cervical metastatic LNs. Round shape, absence of hilar structure, peripheral or mixed blood flow and centripetal or mass enhancement were risk factors for lymph node metastases. The area under the receiver operating characteristic curve of the nomogram model based on conventional US and CEUS features was 0.93 (95% confidence interval: 0.872-0.985), which was superior to that of the nomogram based on conventional US features(0.85, 95% confidence interval: 0.707-0.989). CEUS features can provide incremental benefit in the diagnosis of LNM among DTC cohorts. Nomograms based on conventional US and CEUS features can predict LN status with high accuracy.
Collapse
Affiliation(s)
- Qianqian Guo
- Department of Ultrasound, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuannanli No. 17, Chaoyang District, Beijing 100021, China
| | - Chao Sun
- Department of Ultrasound, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuannanli No. 17, Chaoyang District, Beijing 100021, China
| | - Qing Chang
- Department of Ultrasound, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuannanli No. 17, Chaoyang District, Beijing 100021, China
| | - Yong Wang
- Department of Ultrasound, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuannanli No. 17, Chaoyang District, Beijing 100021, China
| | - Yu Chen
- Department of Ultrasound, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuannanli No. 17, Chaoyang District, Beijing 100021, China
| | - Qian Wang
- Department of Ultrasound, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuannanli No. 17, Chaoyang District, Beijing 100021, China
| | - Zhengjiang Li
- Department of Head and Neck Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Lijuan Niu
- Department of Ultrasound, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuannanli No. 17, Chaoyang District, Beijing 100021, China.
| |
Collapse
|
21
|
Papillary Thyroid Carcinoma: Current Position in Epidemiology, Genomics, and Classification. METHODS IN MOLECULAR BIOLOGY (CLIFTON, N.J.) 2022; 2534:1-15. [PMID: 35670964 DOI: 10.1007/978-1-0716-2505-7_1] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Papillary thyroid carcinoma is the most common type of thyroid malignancy both in adults and pediatric population. Since the 1980s, there are changes in criteria in labelling thyroid lesions as "papillary thyroid carcinomas." Radiation exposure is a well-established risk factor for papillary thyroid carcinoma. Other environmental risk factors include dietary iodine, obesity, hormones, and environmental pollutants. Papillary thyroid carcinomas could occur in familial settings, and 5% of these familial cases have well-studied driver germline mutations. In sporadic papillary thyroid carcinoma, BRAF mutation is common and is associated with clinicopathologic and prognostic markers. The mutation could aid in the clinical diagnosis of papillary thyroid carcinoma. Globally, thyroid cancer is among the top ten commonest cancer in females. In both adult and pediatric populations, there are variations of prevalence of thyroid cancer and rising incidence rates of thyroid cancer worldwide. The increase of thyroid cancer incidence was almost entirely due to the increase of papillary thyroid carcinoma. The reasons behind the increase are complex, multifactorial, and incompletely understood. The most obvious reasons are increased use of diagnostic entities, change in classification of thyroid neoplasms, as well as factors such as obesity, environmental risk factors, and radiation. The prognosis of the patients with papillary thyroid carcinoma is generally good after treatment. Nevertheless, cancer recurrence and comorbidity of second primary cancer may occur, and it is important to have awareness of the clinical, pathological, and molecular parameters of papillary thyroid carcinoma.
Collapse
|
22
|
Leitch K, Halicek M, Shahedi M, Little JV, Chen AY, Fei B. Detecting Aggressive Papillary Thyroid Carcinoma Using Hyperspectral Imaging and Radiomic Features. PROCEEDINGS OF SPIE--THE INTERNATIONAL SOCIETY FOR OPTICAL ENGINEERING 2022; 12033:1203322. [PMID: 36798628 PMCID: PMC9929637 DOI: 10.1117/12.2611842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Hyperspectral imaging (HSI) and radiomics have the potential to improve the accuracy of tumor malignancy prediction and assessment. In this work, we extracted radiomic features of fresh surgical papillary thyroid carcinoma (PTC) specimen that were imaged with HSI. A total of 107 unique radiomic features were extracted. This study includes 72 ex-vivo tissue specimens from 44 patients with pathology-confirmed PTC. With the dilated hyperspectral images, the shape feature of least axis length was able to predict the tumor aggressiveness with a high accuracy. The HSI-based radiomic method may provide a useful tool to aid oncologists in determining tumors with intermediate to high risk and in clinical decision making.
Collapse
Affiliation(s)
- Ka’Toria Leitch
- Department of Bioengineering, University of Texas at Dallas, Richardson, TX
| | - Martin Halicek
- Department of Bioengineering, University of Texas at Dallas, Richardson, TX
| | - Maysam Shahedi
- Department of Bioengineering, University of Texas at Dallas, Richardson, TX
| | - James V. Little
- Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA
| | - Amy Y. Chen
- Department of Otolaryngology, Emory University School of Medicine, Atlanta, GA
| | - Baowei Fei
- Department of Bioengineering, University of Texas at Dallas, Richardson, TX
- Department of Radiology, The University of Texas Southwestern Medical Center, Dallas, TX
| |
Collapse
|